

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

This report highlights all changes (additions, deletions and removals) to the CVS/caremark Performance Drug List.

ADDITIONS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Aranesp (darbepoetin alfa)	Hematologic/ Hematopoietic Growth Factors	Aranesp is indicated for the treatment of anemia due to: <ul style="list-style-type: none"> • Chronic kidney disease (CKD) in patients on dialysis and patients not on dialysis. • The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. 	To provide a long-acting erythropoiesis stimulating agent therapy option on the Performance Drug List.
Bidil (isosorbide dinitrate/ hydralazine)	Cardiovascular/ Nitrate/Vasodilator Combinations	BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status.	To provide an adjunct combination therapy option for selected patients with heart failure.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Ciprodex (ciprofloxacin/ dexamethasone)	Topical/ Otic/Anti-infective/Anti- inflammatory Combinations	Ciprodex is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: <ul style="list-style-type: none"> • Acute otitis media in pediatric patients (age six months of age and older) with tympanostomy tubes due to susceptible organisms. • Acute otitis externa in pediatric (age six months of age and older), adult and elderly patients due to susceptible organisms. 	To provide an additional combinations therapy option for the treatment of otitis media and otitis externa.
Glucagen Hypokit (glucagon, human recombinant)	Endocrine and Metabolic/ Glucose Elevating Agents	GlucaGen is indicated for: <ul style="list-style-type: none"> • Treatment of severe hypoglycemia. • Use as a diagnostic aid. 	To provide a therapy option for the treatment of severe hypoglycemic events in patients with diabetes who are receiving insulin.
Glucagon Emergency Kit (glucagon, human recombinant)	Endocrine and Metabolic/ Glucose Elevating Agents	Glucagon is indicated: <ul style="list-style-type: none"> • As a treatment for severe hypoglycemia. • For use as a diagnostic aid. 	To provide a therapy option for the treatment of severe hypoglycemic events in patients with diabetes who are receiving insulin.
Invokamet (canagliflozin/	Endocrine and Metabolic/ Antidiabetics/	Invokamet is indicated as an adjunct to diet and exercise to	To provide a fixed-dose combination therapy option containing canagliflozin and metformin which could

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
metformin)	Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor/Biguanide Combinations	improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing metformin or canagliflozin or in patients already being treated with both canagliflozin and metformin.	improve adherence and convenience in patients with type 2 diabetes. Adjudication change will go into effect on 12/1/2014.
Megace ES (megestrol acetate) suspension	Endocrine and Metabolic/ Progestins/Oral	Megace ES oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome.	To provide an oral suspension formulation therapy option for appetite stimulation.
Myrbetriq (mirabegron extended-release [ER])	Genitourinary/ Urinary Antispasmodics	Myrbetriq is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.	To provide an additional oral therapy option with an alternative mechanism of action and potential for fewer adverse events for the treatment of overactive bladder.
Nuvigil (armodafinil)	Central Nervous System/ Narcolepsy	Nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with treated obstructive sleep	To provide an effective therapy option for the treatment of narcolepsy.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary
Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		apnea, narcolepsy, or shift work disorder.	
Procrit (epoetin alfa)	Hematologic/ Hematopoietic Growth Factors	Procrit is indicated for: • Treatment of anemia due to - CKD in patients on dialysis and not on dialysis. - Zidovudine in human immunodeficiency virus-infected patients. - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. • Reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery.	To provide an erythropoiesis stimulating agent therapy option on the Performance Drug List.
Proctofoam-HC (hydrocortisone acetate/pramoxine) foam	Gastrointestinal/ Steroids, Rectal	Proctofoam-HC is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the anal region.	To provide an additional Food and Drug Administration (FDA)-approved rectal corticosteroid therapy option.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Pylera (bismuth/ metronidazole/ tetracycline)	Gastrointestinal/ Ulcer Therapy Combinations	Pylera is indicated for the treatment of patients with <i>Helicobacter pylori</i> infection and duodenal ulcer disease (active or history of within the past five years) to eradicate <i>H. pylori</i> .	To provide an additional therapy option for <i>H. pylori</i> infection with improved convenience for patients compared with multiple agents administered separately.
Ranexa (ranolazine ER)	Cardiovascular/ Miscellaneous	Ranexa is indicated for the treatment of chronic angina.	To provide an additional therapy option with an alternative mechanism of action for the treatment of symptomatic relief of angina.
Relistor (methylnaltrexone)	Gastrointestinal/ Miscellaneous	Relistor is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.	To provide a therapy option for the treatment of opioid-induced constipation.
Silenor (doxepin)	Central Nervous System/ Hypnotics/Tricyclics	Silenor is indicated for the treatment of insomnia characterized by difficulties with sleep maintenance.	To provide an additional therapy option for the treatment of insomnia with an alternative mechanism of action than currently listed products.
Uceris (budesonide ER)	Gastrointestinal/ Inflammatory Bowel Disease/ Oral Agents	Uceris is indicated for the induction of remission in patients with active, mild to moderate	To provide the only FDA-approved formulation of budesonide for the treatment of ulcerative colitis.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		ulcerative colitis.	
Xifaxan 550 mg (rifaximin)	Anti-infectives/ Miscellaneous	Xifaxan 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age and older.	To provide an effective therapy option for prevention of HE recurrence.
Generic Agents:			
azelastine	Respiratory/ Nasal Antihistamines	Astepro is indicated for the relief of the symptoms of seasonal and perennial allergic rhinitis in patients six years of age and older.	The "A"-rated generic azelastine will replace the branded agent Astepro (azelastine) on the Performance Drug List.
cyclobenzaprine	Central Nervous System/ Musculoskeletal Therapy Agents	Cyclobenzaprine is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.	To provide an additional generic therapy option.
eszopiclone	Central Nervous System/ Hypnotics, Nonbenzodiazepines	Eszopiclone is indicated for the treatment of insomnia.	To provide an additional generic therapy option.
methoxsalen oral	Topical/ Dermatology/Antipsoriatics/ Oral	Photochemotherapy (methoxsalen with long wave ultraviolet A [UVA] radiation) is indicated for the	The "A"-rated generic methoxsalen oral will replace the branded agent Oxsoalene-Ultra (methoxsalen) oral on the Performance Drug List.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. Methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long wave UV.	
telmisartan	Cardiovascular/ Angiotensin II Receptor Antagonists/Diuretic Combinations	Telmisartan is indicated for: <ul style="list-style-type: none"> • Treatment of hypertension, to lower blood pressure. • Cardiovascular risk reduction in patients unable to receive angiotensin-converting enzyme (ACE) inhibitors. 	The “A”-rated generic telmisartan will replace the branded agent Micardis (telmisartan) on the Performance Drug List.
valsartan	Cardiovascular/ Angiotensin II Receptor Antagonists/Diuretic Combinations	Valsartan is indicated for: <ul style="list-style-type: none"> • Treatment of hypertension, to lower blood pressure. • Treatment of heart failure (New York Heart Association [NYHA] class II to V). • Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure 	The “A”-rated generic valsartan will replace the branded agent Diovan (valsartan) on the Performance Drug List.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		or left ventricular dysfunction following myocardial infarction.	

DELETIONS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Astepro (azelastine) spray	Respiratory/ Nasal Antihistamines	Astepro is indicated for the relief of the symptoms of seasonal and perennial allergic rhinitis in patients six years of age and older.	Astepro (azelastine) will be replaced on the Performance Drug List by the "A"-rated generic azelastine.
Diovan (valsartan)	Cardiovascular/ Angiotensin II Receptor Antagonists/Diuretic Combinations	Diovan is indicated for: <ul style="list-style-type: none"> • Treatment of hypertension, to lower blood pressure. • Treatment of heart failure (NYHA class II to IV). • Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction. 	Diovan (valsartan) will be replaced on the Performance Drug List by the "A"-rated generic valsartan.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Incivek (telaprevir)	Anti-infectives/ Antivirals/Hepatitis C Agents	Incivek is indicated, in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers.	Incivek (telaprevir) is being discontinued by the manufacturer. Preferred options on the Performance Drug List include ribavirin, Sovaldi (sofosbuvir) and Victrelis (boceprevir).
Micardis (telmisartan)	Cardiovascular/ Angiotensin II Receptor Antagonists/Diuretic Combinations	Micardis is indicated for: <ul style="list-style-type: none"> • Treatment of hypertension, to lower blood pressure. • Cardiovascular risk reduction in patients unable to receive ACE inhibitors. 	Micardis (telmisartan) will be replaced on the Performance Drug List by the "A"-rated generic telmisartan.
Oxsoralen-Ultra (methoxsalen) oral	Topical/ Dermatology/Antipsoriatics/ Oral	Photochemotherapy (methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis	Oxsoralen-Ultra (methoxsalen) oral will be replaced on the Performance Drug List by the "A"-rated generic methoxsalen oral.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.



Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		has been supported by biopsy. Methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation.	

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

REMOVALS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Accu-Chek kits and strips	Endocrine and Metabolic/ Antidiabetics/Supplies	Not applicable.	Availability of additional diabetes testing supplies (kits and strips). Preferred options on the Prescribing Guide are OneTouch Ultra strips and kits and OneTouch Verio strips and kits.
Adderall XR (amphetamine/ dextroamphetamine mixed salts ER)	Central Nervous System/ Attention Deficit Hyperactivity Disorder	Adderall XR is indicated for the treatment of ADHD.	Availability of a generic therapy option. A preferred option on the Prescribing Guide is amphetamine/dextroamphetamine mixed salts ER.
Adrenaclick (epinephrine)	Respiratory/ Anaphylaxis Treatment Agents	Adrenaclick is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as anaphylaxis to unknown substances or exercise-induced	Availability of additional therapeutically interchangeable treatment options with the same active ingredient. Preferred options on the Prescribing Guide are Auvi-Q (epinephrine), EpiPen (epinephrine) and EpiPen Jr. (epinephrine).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		anaphylaxis.	
Aerospan (flunisolide) CFC-free aerosol	Respiratory/ Steroid Inhalants	Aerospan is indicated for: <ul style="list-style-type: none"> • Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age and older. • Asthma patients requiring oral corticosteroid therapy, where adding Aerospan inhalation aerosol may reduce or eliminate the need for oral corticosteroids. 	Availability of additional therapy options. Preferred options on the Prescribing Guide are Asmanex (mometasone), Flovent Diskus (fluticasone), Flovent HFA (fluticasone, CFC-free aerosol), Pulmicort Flexhaler (budesonide) and QVAR (beclomethasone, CFC-free aerosol).
Amrix (cyclobenzaprine ER)	Central Nervous System/ Musculoskeletal Therapy Agents	Amrix is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.	Availability of a generic therapy option. A preferred option on the Prescribing Guide is cyclobenzaprine.
Apexicon E (diflorasone diacetate) 0.05% emollient cream	Topical/ Dermatology/Corticosteroids/ High Potency	Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.	Availability of generic therapy options. Preferred options on the Prescribing Guide are desoximetasone and fluocinonide.
Apidra (insulin glulisine)	Endocrine and Metabolic/ Antidiabetics/Insulins	Apidra is indicated to improve glycemic control in adults and	Availability of an additional rapid-acting insulin therapy option with no clinically relevant differences in safety,

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		children with diabetes.	efficacy or administration. A preferred option on the Prescribing Guide is Novolog (insulin aspart).
Byetta (exenatide)	Endocrine and Metabolic/ Antidiabetics/ Incretin Mimetic Agents	Byetta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.	Availability of additional therapy options with superior reduction in hemoglobin A1C and better gastrointestinal tolerability. Preferred options on the Prescribing Guide are Bydureon (exenatide ER) and Victoza (liraglutide).
Duexis (ibuprofen/ famotidine)	Analgesics/ NSAIDs, Combinations	Duexis is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis (OA) and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are receiving ibuprofen for those indications.	Availability of additional brand and generic NSAIDs and gastroprotective components of the fixed-dose combination product. Preferred options on the Prescribing Guide are Celebrex (celecoxib); diclofenac sodium, meloxicam or naproxen WITH lansoprazole, omeprazole, omeprazole/sodium bicarbonate capsule, pantoprazole, Dexilant (dexlansoprazole DR) or Nexium (esomeprazole DR).
Euflexxa (sodium hyaluronate)	Analgesics/ Viscosupplements	Euflexxa is indicated for the treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic	Availability of additional therapy options. Preferred options on the Prescribing Guide are Gel-One (sodium hyaluronate), Hyalgan (sodium hyaluronate) and Supartz (sodium hyaluronate).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		therapy and simple analgesics (e.g., acetaminophen).	
Farxiga (dapagliflozin)	Endocrine and Metabolic/ Antidiabetics/ Sodium-Glucose Co- transporter 2 (SGLT2) Inhibitors	Farxiga is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.	Availability of additional therapy option with no clinically relevant differences in safety or efficacy. A preferred option on the Prescribing Guide is Invokana (canagliflozin).
Lunesta (eszopiclone)	Central Nervous System/ Hypnotics, Nonbenzodiazepines	Lunesta is indicated for the treatment of insomnia.	Availability of additional therapy options. Preferred options on the Prescribing Guide are eszopiclone, zolpidem, zolpidem ER and Silenor (doxepin).
Naprelan (naproxen sodium ER)	Analgesics/ NSAIDs	Naprelan is indicated: • For the treatment of rheumatoid arthritis, OA, ankylosing spondylitis, tendinitis, bursitis and acute gout. • In the relief of mild to moderate pain and the treatment of primary dysmenorrhea.	Availability of additional therapy options with no clinically relevant differences in safety, efficacy or route of administration. Preferred options on the Prescribing Guide are diclofenac sodium, meloxicam, naproxen and Celebrex (celecoxib).
Natesto (testosterone) nasal gel	Endocrine and Metabolic/ Androgens	Natesto is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:	Availability of additional therapy options with no clinically relevant differences in safety and efficacy. Preferred options on the Prescribing Guide are Androderm (testosterone) transdermal, Axiron

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> • Primary hypogonadism (congenital or acquired) • Hypogonadotropic hypogonadism (congenital or acquired) 	<p>(testosterone) solution and Fortesta (testosterone) gel.</p> <p>Natesto is not yet available.</p>
Norvasc (amlodipine)	Cardiovascular/ Calcium Channel Blockers/ Dihydropyridines	<p>Norvasc may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of:</p> <ul style="list-style-type: none"> • Hypertension, to lower blood pressure. • Coronary artery disease 	<p>Availability of a generic therapy option.</p> <p>A preferred option on the Prescribing Guide is amlodipine.</p>
Orthovisc (hyaluronan)	Analgesics/ Viscosupplements	<p>Orthovisc is indicated in the treatment of pain in OA of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).</p>	<p>Availability of additional therapy options.</p> <p>Preferred options on the Prescribing Guide are Gel-One (sodium hyaluronate), Hyalgan (sodium hyaluronate) and Supartz (sodium hyaluronate).</p>
Pennsaid (diclofenac sodium) solution 1.5%/2%	Analgesics/ NSAIDs, Topical	<p>Pennsaid is used for treating the pain of OA of the knee(s).</p>	<p>Availability of additional brand and generic topical therapy options for the treatment of OA of the knee.</p> <p>Preferred options on the Prescribing Guide are diclofenac sodium, diclofenac sodium solution 1.5%, meloxicam,</p>

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
			naproxen and Voltaren Gel (diclofenac sodium).
Proventil HFA (albuterol sulfate) CFC-free aerosol	Respiratory/ Beta Agonists/Inhalants/ Short Acting	Proventil HFA is indicated in adults and children four years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.	Availability of additional therapeutically interchangeable treatment options with the same active ingredient. A preferred option on the Prescribing Guide is Proair HFA (albuterol sulfate) CFC-free aerosol.
Rebif (interferon beta-1a)	Central Nervous System/ Multiple Sclerosis Agents	Rebif is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability.	Availability of additional interferon therapy options for the treatment of multiple sclerosis. Preferred options on the Prescribing Guide are Avonex (interferon beta-1a), Copaxone (glatiramer), Extavia (interferon beta-1b), Gilenya (fingolimod) and Tecfidera (dimethyl fumarate DR).
Symbicort (budesonide/ formoterol)	Respiratory/ Steroid/Beta Agonist Combinations	Symbicort is indicated for: <ul style="list-style-type: none"> • Treatment of asthma in patients twelve years of age and older. • Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. 	Availability of additional therapy options with no clinically relevant differences in safety and efficacy. Preferred options on the Prescribing Guide are Advair (fluticasone/salmeterol) and Dulera (mometasone/formoterol).
Vimovo	Analgesics/	Vimovo is indicated for relief of	Availability of additional brand and generic NSAIDs and

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.

Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
(naproxen/ esomeprazole DR)	NSAIDs, Combinations	signs and symptoms of OA, rheumatoid arthritis and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID associated gastric ulcers.	gastroprotective components of the fixed-dose combination product. Preferred options on the Prescribing Guide are Celebrex (celecoxib); diclofenac sodium, meloxicam or naproxen WITH lansoprazole, omeprazole, omeprazole/sodium bicarbonate capsule, pantoprazole, Dexilant (dexlansoprazole DR) or Nexium (esomeprazole DR).
Vogelxo (testosterone) gel	Endocrine and Metabolic/ Androgens	Vogelxo is indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: <ul style="list-style-type: none"> • Primary hypogonadism (congenital or acquired) • Hypogonadotropic hypogonadism 	Availability of additional therapeutically interchangeable treatment options with the same active ingredient. Preferred options on the Prescribing Guide are Androderm (testosterone) transdermal, Axiron (testosterone) solution and Fortesta (testosterone) gel.
Generic Agents:			
testosterone gel	Endocrine and Metabolic/ Androgens	Testosterone gel is indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: <ul style="list-style-type: none"> • Primary hypogonadism (congenital or acquired) • Hypogonadotropic hypogonadism 	Availability of additional therapeutically interchangeable treatment options with the same active ingredient. Preferred options on the Prescribing Guide are Androderm (testosterone) transdermal, Axiron (testosterone) solution and Fortesta (testosterone) gel.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.



Performance Drug List Change Summary Report

Effective 01-01-2015

(Standard Drug List Reflects Removals)

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		hypogonadism	

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS/caremark.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2014 CVS/caremark. All rights reserved.